Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat

International Journal of Toxicology

Volumn 29, Issue 1, 2010, Pages 3-19

  Kerr, Janet S ^a   Galloway, Sheila ^a   Lagrutta, Armando ^a   Armstrong, Michael ^a   Miller, Thomas ^a   Richon, Victoria M ^a   Andrews, Paul A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b EISAI INC   (United States)

Author keywords

Genotoxicity; Histone deacetylase; Safety pharmacology; Toxicity; Vorinostat

Indexed keywords

VORINOSTAT; DNA; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; BONE MARROW; CHO CELL; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOG; FEMALE; FOOD INTAKE; GASTROINTESTINAL TOXICITY; GENOTOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY; LIVER; MALE; MICRONUCLEUS TEST; MUTAGENICITY; NONHUMAN; ORGAN WEIGHT; RAT; RISK ASSESSMENT; SEMINAL VESICLE; THYMUS; TOXICOKINETICS; WEIGHT REDUCTION; ANIMAL; BLOOD CELL; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; CRICETULUS; DRUG EFFECT; DRUG SCREENING; EATING; GENETICS; HAMSTER; MICRONUCLEUS; MOUSE; PATHOLOGY; SALMONELLA TYPHIMURIUM; STOMACH MUCOSA; STOMACH ULCER; TOXICITY TESTING;

CANIS FAMILIARIS; RATTUS; RODENTIA;

ANIMALS; BLOOD CELLS; BODY WEIGHT; CHO CELLS; CRICETINAE; CRICETULUS; DNA; DOGS; DRUG EVALUATION, PRECLINICAL; EATING; ENZYME INHIBITORS; GASTRIC MUCOSA; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; RATS; SALMONELLA TYPHIMURIUM; STOMACH ULCER; TOXICITY TESTS; WEIGHT LOSS;

EID: 77949886046     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809352111     Document Type: Article

References (50)

1. Khan O, La Thangue NB. Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol. 2008;5:714-726.
2. De Ruijter AJM, Van Gennip AH, Caron HN, Demp S, Van Kuilenbur ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737-749.
3. Yang W-M, Yao Y-L, Sun J-M, et al. Isolation and characterization of cDNA corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem. 1997;272:28001-28007.
4. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone deacetylase. Proc Natl Acad Sci U S A. 2000;97:10014-10019.
5. Pheil DJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734-36741. (Pubitemid 37384288)
6. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007;13:2318-2322. (Pubitemid 46698579)
7. Garber K. HDAC inhibitors overcome first hurdle. Nat Biotechnol. 2007;25:17-19. (Pubitemid 46087886)
8. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84-90. (Pubitemid 46087907)
9. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009;280:201-210.
10. Wise LD, Turner KJ, Kerr JS. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res (Part B). 2007;80:57-68.
11. Wise LD, Spence S, Saldutti LP, Kerr JS. Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor. Birth Defects Res (Part B). 2008;83:19-26.
12. OECD, Bacterial reverse mutation test. OECD Guidelines for Testing of Chemicals, Section 4, Guideline 471 updated and adopted July 21, 1997. http://oberon.sourceoecd.org/vl=686174/cl=21/nw=1/rpsv/cw/vhosts/oecdjournals/ 1607310x/v1n4/contp1-1.htm. Accessed October 25, 2009.
13. OECD, In vitro mammalian chromosome aberration test. OECD Guidelines for Testing of Chemicals, Section 4, Guideline 473 updated and adopted July 21, 1997. http://oberon.sourceoecd.org/vl=686174/cl=21/nw=1/rpsv/cw/vhosts/ oecdjournals/1607310x/v1n4/contp1-1.htm. Accessed October 25, 2009.
14. OECD, Mammalian erythrocyte micronucleus test. OECD Guidelines for Testing of Chemicals, Section 4, Guideline 474 adopted 21 Jul 1997. http://oberon.sourceoecd.org/vl=686174/cl=21/nw=1/rpsv/cw/vhosts/oecdjournals/ 1607310x/v1n4/contp1-1.htm. Accessed October 25, 2009.
15. Galloway SM, Aardema MJ, Ishidate M Jr, et al. Report from working group on in vitro tests for chromosomal aberrations. Mutat Res. 1994;312:1-261.
16. Hilliard C, Hill R, Armstrong M, et al. Chromosome aberrations in Chinese hamster and human cells: a comparison using compounds with various genotoxicity profiles. Mutat Res. 2007;616:103-118.
17. Galloway SM, Miller JE, Armstrong MJ, et al. DNA synthesis inhibition as an indirect mechanism of chromosome aberrations: comparison of DNA-reactive and non-DNA-reactive clastogens. Mutat Res. 1998;400:169-186.
18. Ames BN, McCann J, Yamasaki E. Methods for detecting mutagens with Salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975;31:347-364.
19. Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res. 1983;113:173-215. (Pubitemid 13120319)
20. Miller JE, Vlasakova K, Glaab WE, Skopek TR. A low volume, high-throughput forward mutation assay in Salmonella typhimurium based on fluorouracil resistance. Mutat Res. 2005;578:210-224.
21. Glaab WE, Mitchell LS, Miller JE, et al. 5-Fluorouracil forward mutation assay in Salmonella: determination of mutational target and spontaneous mutational spectra. Mutat Res. 2005;578:238-246.
22. Sun JT, Armstrong MJ, Galloway SM. Rapid method for improving slide quality in the bone marrow micronucleus assay; an adapted cellulose column procedure. Mutat Res. 1999;439:121-126.
23. Lagrutta A, Wang JX, Fermini B, Salata J. Novel, potent inhibitors of human Kv1.5K+ channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther. 2006;317:1054-1063. (Pubitemid 43764108)
24. Trepakova ES, Dech SJ, Salata JJ. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current. J Cardiovasc Pharm. 2006;47:211-220.
25. Gauvin DV, Tilley LP, Smith FWK Jr, Baird TJ. Electrocardiogram, hemodynamics and core body temperatures of the normal freely moving laboratory beagle dog by remote radiotelemetry. J Pharm Tox Methods. 2006;53:128-139. (Pubitemid 43295660)
26. Chaves AA, Zingaro GJ, Yordy MA, et al. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. J Pharm Tox Methods. 2007;56:103-114.
27. Fridericia L. Die systolendauer in elektrokardiogramm bei normalen menschen und beiherzkranken. Acta Med Scand. 1920;53:469-486.
28. Redfern WS, Strang I, Storey S, et al. Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds. J Pharm Tox Methods. 2005;52:77-82. (Pubitemid 41008631)
29. Moscardo E, Maurin A, Dorigatti R, et al. An optimised methodology for the neurobehavioural assessment in rodents. J Pharm Tox Methods. 2007;56:239-255. (Pubitemid 47376971)
30. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for change in heart rate. J Pharm Methods. 1989;22:207-217. (Pubitemid 19275446)
31. Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br. J Cancer. 2006;95:S2-S6. (Pubitemid 44950782)
32. Skipper PL, Tannenbaum SR, Thilly WG, et al. Mutagenicity of hydroxamic acids and the probable involvement of carbamoylation. Cancer Res. 1980;40:4704-4708.
33. Beck DJ, Fisch JE. Mutagenicity of platinum coordination complexes in Salmonella typhimurium. Mutat Res. 1980;77:45-54. (Pubitemid 10163610)
34. Olaharski AJ, Ji Z, Woo J-Y, et al. The histone deacetylase inhibitor Trichostatin A has genotoxic effects in human lymphoblasts in vitro. Toxicol Sci. 2006;93:341-347. (Pubitemid 44400452)
35. Yoo EJ, Lee BM. Comparative mutagenicity of apicidin and apicidin derivatives (SD-0203 and SD-2007), histone deacetylase inhibitors. J Toxicol Environ Health Part A. 2005;68:2097-2109.
36. Hu T, Miller CM, Ridder GM, Aardema M. Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL and CHL; implications for genotoxicity testing. Mutat Res. 1999;426:51-62.
37. Kung A, Sherwood S, Schimke R. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci U S A. 1990;87:9553-9557. (Pubitemid 120016481)
38. Schimke R, Kung A, Rush D, Sherwood S. Differences in mitotic control among mammalian cells. Cold Spring Harb Symp Quant Biol. 1991;LVI:417-425.14.
39. Qiu L, Burgess A, Fairlie DP, et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell. 2000;11:2069-2083. (Pubitemid 30408065)
40. Shin H-J, Baek K-W, Jeaon A-E, et al. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene. 2003;22:3853-3858.
41. Stevens FE, Beamish H, Warrener R, Gabrelli B. Histone deacetylase inhibitors induce mitotic slippage. Oncogene. 2008;27:1345-1354. (Pubitemid 351317466)
42. Xu W-S, Perez G, Ngo L, et al. Induction of polyploidy by histone deacetylase inhibitors: a pathway for antitumor effects. Cancer Res. 2008;54:7832-7839.
43. Cimini D, Mattiuzzo M, Torosantucci L, Degrassi L. Histone deactylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell. 2003;14:3821-3833. (Pubitemid 37151628)
44. Tweats DJ, Blakey D, Heflich RH, et al. Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests. I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards. Mutat Res. 2007;627:78-91.
45. Rowinsky EK, de Bono J, Deangelo DJ, et al. Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies [abstract 3131]. J Clin Oncol. 2005;23:22.
46. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628-4635. (Pubitemid 44297814)
47. Kelly WK, O'Conner OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923-3931.
48. Munster PN, Rubin EH, Van Belle S et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res. 2009; in press. Doi:10.1158/1078-0432.CCR-09-1214.
49. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12:3997-4003. (Pubitemid 44078086)
50. Sandhu P, Andrews PA, Baker MP, et al. Disposition of vorinostat, a novel histone deacetylase inhibitor and anti-cancer agent, in preclinical species. Drug Metab Lett. 2007;1:153-161.